SEC Comment Letter for Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750) (VRDN) — Dec 18, 2020

Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750)
Date: Dec. 18, 2020 · CIK: 0001590750 · Accession: 0000000000-20-012180

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-36483

Date

December 17, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Viridian Therapeutics, Inc.\DE (VRDN) (CIK 0001590750)

Letter

United States securities and exchange commission logo December 17, 2020 Lee Rauch Chief Executive Officer Miragen Therapeutics, Inc. 6200 Lookout Road Boulder, CO 80301 Re:Miragen Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed November 20, 2020 File No. 001-36483 Dear Ms. Rauch: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Murr, Esq.

Show Raw Text

United States securities and exchange commission logo
December 17, 2020
Lee Rauch
Chief Executive Officer
Miragen Therapeutics, Inc.
6200 Lookout Road
Boulder, CO 80301
Re:Miragen Therapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed November 20, 2020
File No. 001-36483
Dear Ms. Rauch:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Ryan Murr, Esq.

SecProbe.io